Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
2.78 USD -2.46% Intraday chart for Anebulo Pharmaceuticals, Inc. -4.30% +14.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Anebulo Pharmaceuticals Appoints New CEO MT
Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO CI
Anebulo Pharmaceuticals, Inc. Appoints Bimal Shah to Its Board of Directors CI
Anebulo Pharmaceuticals Appoints Daniel George as Part-Time Finance Chief MT
Anebulo Pharmaceuticals, Inc. Announces Chief Financial Officer Changes CI
Anebulo Pharmaceuticals, Inc. Appoints Daniel George as Principal Financial Officer and Principal Accounting Officer CI
Maxim Starts Anebulo Pharmaceuticals at Buy With $6 Price Target MT
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023 CI
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer MT
HC Wainwright Initiates Anebulo Pharmaceuticals With Buy Rating, Price Target is $6 MT
Anebulo Pharmaceuticals, Inc. Announces Resignation of Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer CI
Anebulo Pharmaceuticals, Inc. Announces Sandra A. Gardiner Resigns as Acting Chief Financial Officer CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Anebulo Pharmaceuticals Reports Positive Data from Trial of Cannabinoid Intoxication Treatment; Shares Jump MT
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of Aneb-001 as A Treatment for Acute Cannabinoid Intoxication CI
Anebulo Pharmaceuticals Appoints Sandra Gardiner as Acting Chief Financial Officer MT
Anebulo Pharmaceuticals, Inc. Appoints Sandra Gardiner as Acting Chief Financial Officer CI
Benchmark Adjusts Anebulo Pharmaceuticals' Price Target to $8 From $10, Keeps Speculative Buy Rating MT
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director CI
Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors CI
Chart Anebulo Pharmaceuticals, Inc.
More charts
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.78 USD
Average target price
6 USD
Spread / Average Target
+115.83%
Consensus
  1. Stock Market
  2. Equities
  3. ANEB Stock
  4. News Anebulo Pharmaceuticals, Inc.
  5. Anebulo Pharmaceuticals Reports Positive Data from Trial of Cannabinoid Intoxication Treatment; Shares Jump